ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
Tym1ng
|
261 |
63K |
3 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
261
|
63K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Final Ethics Approval for Open-Label MND Extension Study
|
|
Tym1ng
|
77 |
18K |
6 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
77
|
18K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Final Ethics Approval for Open-Label MND Extension Study
|
|
Tym1ng
|
77 |
18K |
14 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
77
|
18K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Final Ethics Approval for Open-Label MND Extension Study
|
|
Tym1ng
|
77 |
18K |
12 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
77
|
18K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
NZT gone but hasn't forgotten
|
|
Tym1ng
|
66 |
18K |
4 |
07/04/24 |
07/04/24 |
ASX - By Stock
|
66
|
18K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
NZT gone but hasn't forgotten
|
|
Tym1ng
|
66 |
18K |
5 |
07/04/24 |
07/04/24 |
ASX - By Stock
|
66
|
18K
|
5
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
Tym1ng
|
176 |
51K |
1 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
176
|
51K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
Tym1ng
|
176 |
51K |
5 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
176
|
51K
|
5
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Notification of upcoming expiry of Unlisted Options
|
|
Tym1ng
|
93 |
22K |
8 |
21/03/24 |
21/03/24 |
ASX - By Stock
|
93
|
22K
|
8
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Successfully Passes Efficacy Interim Analysis
|
|
Tym1ng
|
279 |
84K |
9 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
279
|
84K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Singapore Healthcare Day Presentation
|
|
Tym1ng
|
63 |
16K |
8 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
63
|
16K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Singapore Healthcare Day Presentation
|
|
Tym1ng
|
63 |
16K |
11 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
63
|
16K
|
11
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix to Present at Euroz Hartley Institutional Conference
|
|
Tym1ng
|
37 |
9.4K |
11 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
37
|
9.4K
|
11
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Trading Halt
|
|
Tym1ng
|
247 |
74K |
17 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
247
|
74K
|
17
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Successfully Passes Efficacy Interim Analysis
|
|
Tym1ng
|
279 |
84K |
15 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
279
|
84K
|
15
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Application for quotation of securities - DXB
|
|
Tym1ng
|
4 |
1.4K |
3 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
4
|
1.4K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
Tym1ng
|
159 |
50K |
0 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
159
|
50K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
Tym1ng
|
159 |
50K |
4 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
159
|
50K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
Tym1ng
|
159 |
50K |
2 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
159
|
50K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
Tym1ng
|
159 |
50K |
4 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
159
|
50K
|
4
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Tym1ng
|
1.3K |
325K |
0 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
1.3K
|
325K
|
0
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Tym1ng
|
1.3K |
325K |
9 |
02/03/24 |
02/03/24 |
ASX - By Stock
|
1.3K
|
325K
|
9
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Tym1ng
|
1.3K |
325K |
7 |
02/03/24 |
02/03/24 |
ASX - By Stock
|
1.3K
|
325K
|
7
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Tym1ng
|
1.3K |
325K |
3 |
02/03/24 |
02/03/24 |
ASX - By Stock
|
1.3K
|
325K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Tym1ng
|
1.3K |
325K |
6 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
1.3K
|
325K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust media thread
|
|
Tym1ng
|
317 |
79K |
10 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
317
|
79K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust media thread
|
|
Tym1ng
|
317 |
79K |
41 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
317
|
79K
|
41
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust media thread
|
|
Tym1ng
|
317 |
79K |
2 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
317
|
79K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Interim Analyses of Clinical Trials
|
|
Tym1ng
|
185 |
48K |
2 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
185
|
48K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust media thread
|
|
Tym1ng
|
317 |
79K |
8 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
317
|
79K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Positive Phase 1 MEND Study Top-Line Results
|
|
Tym1ng
|
152 |
45K |
13 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
152
|
45K
|
13
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Tym1ng
|
1.3K |
325K |
11 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
1.3K
|
325K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Positive Phase 1 MEND Study Top-Line Results
|
|
Tym1ng
|
152 |
45K |
6 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
152
|
45K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Sparks Valuation Pharmaust
|
|
Tym1ng
|
111 |
34K |
6 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
111
|
34K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Sparks Valuation Pharmaust
|
|
Tym1ng
|
111 |
34K |
11 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
111
|
34K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Positive Phase 1 MEND Study Top-Line Results
|
|
Tym1ng
|
152 |
45K |
5 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
152
|
45K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Presentation - Phase 1 Top-Line Results
|
|
Tym1ng
|
34 |
10K |
14 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
34
|
10K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Presentation - Phase 1 Top-Line Results
|
|
Tym1ng
|
34 |
10K |
17 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
34
|
10K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Presentation - Phase 1 Top-Line Results
|
|
Tym1ng
|
34 |
10K |
11 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
34
|
10K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor webinar - Phase 1 MND Study Top-Line Results
|
|
Tym1ng
|
209 |
49K |
3 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
209
|
49K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor webinar - Phase 1 MND Study Top-Line Results
|
|
Tym1ng
|
209 |
49K |
29 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
209
|
49K
|
29
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor webinar - Phase 1 MND Study Top-Line Results
|
|
Tym1ng
|
209 |
49K |
8 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
209
|
49K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
Tym1ng
|
114 |
33K |
15 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
114
|
33K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
Tym1ng
|
114 |
33K |
10 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
114
|
33K
|
10
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Application for quotation of securities - DXB
|
|
Tym1ng
|
153 |
36K |
10 |
23/02/24 |
23/02/24 |
ASX - By Stock
|
153
|
36K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: EGM Shareholder Presentation
|
|
Tym1ng
|
45 |
13K |
10 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
45
|
13K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Extension Study Begins, Analysis Suggests Survival Benefit
|
|
Tym1ng
|
197 |
51K |
30 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
197
|
51K
|
30
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Extension Study Begins, Analysis Suggests Survival Benefit
|
|
Tym1ng
|
197 |
51K |
14 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
197
|
51K
|
14
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Tym1ng
|
1.3K |
325K |
17 |
18/02/24 |
18/02/24 |
ASX - By Stock
|
1.3K
|
325K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Chart & more
|
|
Tym1ng
|
15 |
5.0K |
4 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
15
|
5.0K
|
4
|
|